<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04402112</url>
  </required_header>
  <id_info>
    <org_study_id>JWP-PTV-712</org_study_id>
    <nct_id>NCT04402112</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pitavastatin in a Real-world Setting</brief_title>
  <acronym>PROOF</acronym>
  <official_title>Efficacy and Safety of Pitavastatin in a Real-wOrld Setting: Observational Study Evaluating saFety in Patient With Pitavastatin for Lipid Lowering Therapy in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prospective, observational, non-comparative trial in South Korea was designed to evaluate
      the efficacy and safety of pitavastatin (Livalo) in clinical practice in 28,343 patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted in 893 facilities in Korea from 2 Apr 2012 to 1 Apr 2017. This study
      was designed to administer 1mg, 2mg, or 4mg pitavastatin to patients with hyperlipidemia at
      the age of 20 or older for at least 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2012</start_date>
  <completion_date type="Actual">August 1, 2017</completion_date>
  <primary_completion_date type="Actual">April 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>At 8 weeks after administration of pitavastatin</time_frame>
    <description>Incidence of musculoskeletal-related adverse events and rhabdomyolysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall symptom satisfaction evaluation</measure>
    <time_frame>At 8 weeks after administration of pitavastatin</time_frame>
    <description>The investigating physician selects one of the followings according to medical judgment: Improvement, constant, exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum lipid profile before and after administration of pitavastatin</measure>
    <time_frame>At screening and after 8 weeks</time_frame>
    <description>Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglyceride</description>
  </secondary_outcome>
  <enrollment type="Actual">28343</enrollment>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>1mg, 2mg, or 4mg, Once a day, at least 8 weeks</description>
    <other_name>LIVALO</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving Livalo tablets in clinical practice in South Korea
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in need of statin treatment who are taking or are planning to take Livalo
             tablets, or who are taking other statins or are planning to change to Livalo tablets.

        Exclusion Criteria:

          -  Patients with hypersensitivity to pitavastatin

          -  Patients with active liver disease or untranslated transaminase levels Patients with a
             constant rise in

          -  Patients with severe liver failure or biliary obstruction and patients with
             cholestasis

          -  Patients who are receiving cyclosporine

          -  Myopathy patients

          -  Pregnant women or women of childbearing age and lactating women

          -  Children

          -  Patients with genetic problems, such as galactose intolerance, Lapp lactose deficiency
             or glucose-galactose

          -  Patients deemed inappropriate by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Rae Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pitavastatin</keyword>
  <keyword>LIVALO</keyword>
  <keyword>Safety data</keyword>
  <keyword>South Korea</keyword>
  <keyword>Large-scale prospective trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

